SCHEMBL31702301

SCHEMBL31702301

CNc1ccc(CC2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.54
PTPN1 P18031 1/20 0.54
PTPN6 P29350 1/20 0.54
KDM4E B2RXH2 1/20 0.53
PKM P14618 1/20 0.53
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
MAPT P10636 2/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
GPR119 Q8TDV5 7/20 0.49
STS P08842 1/20 0.47
ABL1 P00519 1/20 0.47
RIN1 Q13671 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
TGFBR1 P36897 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771631 0.86 GPR119 (0.59) PTPN2PTPN1PTPN6GPR119TGFBR1
SCHEMBL12263494 0.86 KDM4E (0.53) PTPN2PTPN1PTPN6KDM4EPKM
SCHEMBL2250178 0.86 GPR119 (0.60) PTPN2PTPN1PTPN6KDM4EPKM
SCHEMBL16113579 0.86 GPR119 (0.61) KDM4EPKMMAPTGPR119LMNA
SCHEMBL5838070 0.85 PTPN2 (0.55) PTPN2PTPN1PTPN6KDM4EPKM
SCHEMBL27587921 0.85 PTPN2 (0.52) PTPN2PTPN1PTPN6KDM4EPKM
SCHEMBL578839 0.85 FPR2 (0.53) PTPN2PTPN1PTPN6KDM4EPKM
SCHEMBL4773466 0.85 TP53 (0.54) KDM4EPKMGPR119LMNATP53
SCHEMBL3145386 0.85 KDM4E (0.52) PTPN2PTPN1PTPN6KDM4EPKM
SCHEMBL22532739 0.85 KDM4E (0.52) PTPN2PTPN1PTPN6KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 PTPN2 693/4885PTPN1 789/4885PTPN6 497/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B PTPN2 569/4885PTPN1 675/4885PTPN6 447/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 PTPN2 693/4885PTPN1 789/4885PTPN6 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.